ChemoCentryx Inc (OQ:CCXI)

Mar 10, 2020 04:05 pm ET
ChemoCentryx Reports Fourth Quarter and Full Year 2019 Financial Results and Recent Highlights
-- $202 million in cash and investments at year end 2019, plus an additional credit facility of up to $100 million secured in January 2020 -- -- Conference call today at 5:00 p.m. Eastern Time -- MOUNTAIN VIEW, Calif., March 10, 2020 (GLOBE...
Mar 03, 2020 08:30 am ET
ChemoCentryx to Hold Fourth Quarter and Full Year 2019 Financial Results Conference Call on Tuesday, March 10, 2020
ChemoCentryx, Inc., (Nasdaq: CCXI), today announced that the Company's fourth quarter and full year 2019 financial results will be released after market close on Tuesday, March 10, 2020. ChemoCentryx executive management will host a conference call...
Feb 19, 2020 08:30 am ET
ChemoCentryx to Present at the 9th Annual SVB Leerink Global Healthcare Conference
ChemoCentryx, Inc., (Nasdaq: CCXI), today announced that Thomas J. Schall, Ph.D., President and Chief Executive Officer, will present at the 9th Annual SVB Leerink Healthcare Conference on Wednesday, February 26, 2020 at 3:00 p.m. ET. The...
Jan 09, 2020 08:30 am ET
ChemoCentryx Announces Credit Facility of Up to $100 Million with Hercules Capital
ChemoCentryx, Inc., (NASDAQ: CCXI) today announced that the Company has secured a credit facility of up to $100 million provided by Hercules Capital, Inc. (NYSE: HTGC), a leader in customized financing for companies in life sciences and...
Jan 08, 2020 08:30 am ET
ChemoCentryx to Present at the 38th Annual JP Morgan Healthcare Conference
ChemoCentryx, Inc., (Nasdaq: CCXI), today announced that Thomas J. Schall, Ph.D., President and Chief Executive Officer, will present at the 38th Annual JP Morgan Healthcare Conference on Wednesday January 15, 2020 at 1:30 p.m. PT. The conference...
Nov 26, 2019 08:30 am ET
ChemoCentryx to Present at the 31st Annual Piper Jaffray Healthcare Conference
ChemoCentryx, Inc., (Nasdaq: CCXI), today announced that Thomas J. Schall, Ph.D., President and Chief Executive Officer, will present at the 31st Annual Piper Jaffray Healthcare Conference on Wednesday, December 4, 2019 at 2:30 p.m. ET. The...
Nov 25, 2019 04:05 pm ET
ChemoCentryx and VFMCRP Announce Positive Topline Data from Pivotal Phase III ADVOCATE Trial Demonstrating Avacopan’s Superiority Over Standard of Care in ANCA-Associated Vasculitis
ChemoCentryx, Inc., (NASDAQ: CCXI) and Vifor Fresenius Medical Care Renal Pharma (VFMCRP) today announced positive topline data from the pivotal Phase III ADVOCATE trial of avacopan, an orally-administered selective complement 5a receptor...
Nov 05, 2019 08:30 am ET
Presentations at ASN Kidney Week 2019 Highlight Breadth of ChemoCentryx Platform in Treatment of Complement 3 Glomerulopathy (C3G) and Focal Segmental Glomerulosclerosis (FSGS)
ChemoCentryx, Inc., (Nasdaq:CCXI), today announced presentations of its lead drug candidates avacopan, a complement 5a receptor inhibitor, and CCX140, an inhibitor of the chemokine receptor known as CCR2, during the American Society of Nephrology...
Nov 04, 2019 04:05 pm ET
ChemoCentryx Reports Third Quarter 2019 Financial Results and Recent Highlights
-- Data from LUMINA Phase II trials of CCR2 inhibitor CCX140 in Focal Segmental Glomerulosclerosis (FSGS), avacopan ACCOLADE (C3G) and AURORA (HS) trials expected in 2020 -- -- $205 million in cash and investments at September 30, 2019 --...
Oct 28, 2019 08:30 am ET
ChemoCentryx to Hold Third Quarter 2019 Financial Results Conference Call on Monday, November 4, 2019
ChemoCentryx, Inc., (Nasdaq: CCXI), today announced that the Company's third quarter 2019 financial results will be released after market close on Monday, November 4, 2019. ChemoCentryx executive management will host a conference call and webcast...
Sep 24, 2019 08:30 am ET
ChemoCentryx to Host R&D Day on October 1, 2019
ChemoCentryx, Inc., (Nasdaq: CCXI), today announced that it will host an R&D Day on Tuesday, October 1, 2019 beginning at 12:00 p.m. ET in New York City. Key therapeutic areas of focus for the R&D Day will be ANCA-Associated Vasculitis (AAV) and...
Aug 29, 2019 08:30 am ET
ChemoCentryx to Present at Two Upcoming Investor Conferences
ChemoCentryx, Inc., (Nasdaq: CCXI), today announced that Thomas J. Schall, Ph.D., President and Chief Executive Officer, will present at two upcoming investor conferences in September:             BioCentury Newsmakers in the Biotech Industry...
Aug 05, 2019 04:05 pm ET
ChemoCentryx Reports Second Quarter 2019 Financial Results and Recent Highlights
-- Advancing three additional clinical trials; plan to release topline data from five clinical trials over the next 18 months -- -- Conference call today at 5:00 p.m. Eastern Time -- MOUNTAIN VIEW, Calif., Aug. 05, 2019 (GLOBE NEWSWIRE) --...
Aug 01, 2019 08:30 am ET
ChemoCentryx to Present at the Canaccord Genuity 39th Annual Growth Conference
ChemoCentryx, Inc., (Nasdaq: CCXI), today announced that Thomas J. Schall, Ph.D., President and Chief Executive Officer, will present at the Canaccord Genuity 39th Annual Growth Conference on Thursday, August 8, 2019 at 9:30 a.m. ET. The conference...
Jul 31, 2019 08:30 am ET
ChemoCentryx to Hold Second Quarter 2019 Financial Results Conference Call on Monday, August 5, 2019
ChemoCentryx, Inc., (Nasdaq: CCXI), today announced that the Company's second quarter 2019 financial results will be released after market close on Monday, August 5, 2019. ChemoCentryx executive management will host a conference call and webcast...
Jun 11, 2019 08:30 am ET
ChemoCentryx to Present at Two Upcoming Investor Conferences
ChemoCentryx, Inc., (Nasdaq: CCXI), today announced that Thomas J. Schall, Ph.D., President and Chief Executive Officer, will present at two upcoming investor conferences in June: Raymond James Life Sciences and MedTech ConferenceTuesday, June 18,...
May 06, 2019 04:05 pm ET
ChemoCentryx Reports First Quarter 2019 Financial Results and Recent Highlights
ChemoCentryx, Inc., (Nasdaq:CCXI), today announced financial results for the first quarter ended March 31, 2019 and provided an overview of the Company's recent corporate highlights. “Achieving our ambitious objectives for 2019 is on track,” said...
Apr 29, 2019 08:30 am ET
ChemoCentryx to Hold First Quarter 2019 Financial Results Conference Call on Monday, May 6, 2019
ChemoCentryx, Inc., (Nasdaq: CCXI), today announced that the Company's first quarter 2019 financial results will be released after market close on Monday, May 6, 2019. ChemoCentryx executive management will host a conference call and webcast...
Apr 16, 2019 08:20 am ET
Report: Exploring Fundamental Drivers Behind Lincoln National, News Corporation, Macerich, ChemoCentryx, Delek Logistics Partners, and SunCoke Energy Partners — New Horizons, Emerging Trends, and Upco
In new independent research reports released early this morning, Market Source Research released its latest key findings for all current investors, traders, and shareholders of Lincoln National Corporation (NYSE:LNC), News Corporation...
Apr 02, 2019 08:30 am ET
ChemoCentryx to Present at the H.C. Wainwright Global Life Sciences Conference
ChemoCentryx, Inc., (Nasdaq: CCXI), today announced that Thomas J. Schall, Ph.D., President and Chief Executive Officer, will present at the H.C. Wainwright Global Life Sciences Conference on Monday, April 8, 2019 at 9:10 a.m. BST. The conference...
Mar 28, 2019 08:30 am ET
ChemoCentryx Appoints Rita Jain, M.D. to Board of Directors
ChemoCentryx, Inc., (Nasdaq:CCXI), announced today that, effective March 27, 2019, Rita Jain, M.D., Senior Vice President and Chief Medical Officer of Akebia Therapeutics, has been appointed to the Company's Board of Directors. Dr. Jain brings more...
Mar 11, 2019 04:05 pm ET
ChemoCentryx Reports Fourth Quarter and Full Year 2018 Financial Results and Recent Highlights
-- Conference call today at 5:00 p.m. Eastern Time -- MOUNTAIN VIEW, Calif., March 11, 2019 (GLOBE NEWSWIRE) -- ChemoCentryx, Inc., (Nasdaq:CCXI), today announced financial results for the fourth quarter and full year ended December 31,...
Mar 04, 2019 08:30 am ET
ChemoCentryx to Hold Fourth Quarter 2018 Financial Results Conference Call on Monday, March 11, 2019
ChemoCentryx, Inc., (Nasdaq: CCXI), today announced that the Company's fourth quarter 2018 financial results will be released after market close on Monday, March 11, 2019. ChemoCentryx executive management will host a conference call beginning at...
Feb 26, 2019 08:20 am ET
New Research: Key Drivers of Growth for Ellie Mae, Spotify Technology SA, Bristow Group, Teradata, ChemoCentryx, and AgroFresh Solutions — Factors of Influence, Major Initiatives and Sustained Product
In new independent research reports released early this morning, Market Source Research released its latest key findings for all current investors, traders, and shareholders of Ellie Mae, Inc. (NYSE:ELLI), Spotify Technology SA (NYSE:SPOT), Bristow...
Feb 20, 2019 08:30 am ET
ChemoCentryx to Present at the 8th Annual SVB Leerink Global Healthcare Conference
ChemoCentryx, Inc., (Nasdaq: CCXI), today announced that Thomas J. Schall, Ph.D., President and Chief Executive Officer, will present at the 8th Annual SVB Leerink Global Healthcare Conference on Thursday, February 28, 2019 at 10:30 a.m. ET. The...
Jan 24, 2019 08:30 am ET
ChemoCentryx Announces Withdrawal of Phase II-Based Conditional Marketing Authorization (CMA) Application for ANCA-Associated Vasculitis in Europe; Phase III ADVOCATE Trial Data Release Planned for Q4
ChemoCentryx, Inc. and Vifor Fresenius Medical Care Renal Pharma Ltd., a company of Vifor Pharma Group, today announced that in light of the upcoming availability of data from the pivotal Phase III ADVOCATE trial – the largest controlled trial in...
Jan 02, 2019 08:30 am ET
ChemoCentryx to Present at the 37th Annual J.P. Morgan Healthcare Conference
ChemoCentryx, Inc., (Nasdaq: CCXI), today announced that Thomas J. Schall, Ph.D., President and Chief Executive Officer, will present at the 37th Annual J.P. Morgan Healthcare Conference on Wednesday, January 9, 2019 at 1:30 p.m. PST. The...
Nov 29, 2018 04:05 pm ET
ChemoCentryx’s Novel Small Molecule Antagonists of Checkpoint Inhibitors and Chemokine Receptors to be Presented at the American Association for Cancer Research (AACR) Tumor Immunology and Immunothera
ChemoCentryx, Inc., (Nasdaq:CCXI), today announced upcoming presentations on two programs featuring small molecule inhibitors of important therapeutic targets in cancer. ChemoCentryx’s novel small molecules – one which profoundly inhibits the...
Nov 27, 2018 08:50 am ET
New Research Coverage Highlights Ralph Lauren, CECO Environmental, PRA Group, ChemoCentryx, SunCoke Energy Partners, and Delek US — Consolidated Revenues, Company Growth, and Expectations for 2018
In new independent research reports released early this morning, Market Source Research released its latest key findings for all current investors, traders, and shareholders of Ralph Lauren Corporation (NYSE:RL), CECO Environmental Corp....
Nov 20, 2018 08:30 am ET
ChemoCentryx to Present at the 30th Annual Piper Jaffray Healthcare Conference
ChemoCentryx, Inc., (Nasdaq: CCXI), today announced that Thomas J. Schall, Ph.D., President and Chief Executive Officer, will present at the 30th Annual Piper Jaffray Healthcare Conference on Tuesday November 27, 2018 at 8:30 a.m. ET. The...
Nov 08, 2018 04:05 pm ET
ChemoCentryx Reports Third Quarter 2018 Financial Results and Recent Highlights
-- Conference call today at 5:00 p.m. Eastern Time -- MOUNTAIN VIEW, Calif., Nov. 08, 2018 (GLOBE NEWSWIRE) -- ChemoCentryx, Inc., (Nasdaq:CCXI), today announced financial results for the third quarter ended September 30, 2018 and provided an...
Nov 01, 2018 08:30 am ET
ChemoCentryx to Hold Third Quarter 2018 Financial Results Conference Call on Thursday, November 8, 2018
ChemoCentryx, Inc., (Nasdaq: CCXI), today announced that the Company's third quarter 2018 financial results will be released after market close on Thursday, November 8, 2018. ChemoCentryx executive management will host a conference call and webcast...
Oct 25, 2018 01:30 pm ET
Presentations at ASN Kidney Week 2018 Highlight ChemoCentryx Platform in Treatment of ANCA-Associated Vasculitis and Focal Segmental Glomerulosclerosis (FSGS)
ChemoCentryx, Inc., (Nasdaq:CCXI), today announced presentations of its lead drug candidates avacopan, a complement 5a receptor inhibitor, and CCX140, an inhibitor of the chemokine receptor known as CCR2, during the American Society of Nephrology...
Oct 16, 2018 09:20 am ET
Analysis: Positioning to Benefit within ChemoCentryx, Armstrong Flooring, Kornit Digital, NewLink Genetics, Silvercorp Metals, and Halcon Resources — Research Highlights Growth, Revenue, and Consolida
In new independent research reports released early this morning, Market Source Research released its latest key findings for all current investors, traders, and shareholders of ChemoCentryx, Inc. (NASDAQ:CCXI), Armstrong Flooring, Inc. (NYSE:AFI),...
Sep 27, 2018 10:20 pm ET
ChemoCentryx Determines Not to Proceed with Public Offering of Common Stock
ChemoCentryx, Inc. (the "Company" or "ChemoCentryx") (Nasdaq:CCXI) announced today that it will not conclude an offering of shares of its common stock as announced on Wednesday, September 26, 2018. The Company believes that culmination of terms...
Sep 26, 2018 04:01 pm ET
ChemoCentryx Announces Proposed Public Offering of Common Stock
ChemoCentryx, Inc. (Nasdaq:CCXI) announced today that it has commenced an underwritten public offering of $75 million of its common stock.  In connection with this offering, ChemoCentryx plans to grant the underwriters a 30-day option to purchase...
Sep 26, 2018 08:30 am ET
ChemoCentryx to Present at the Cantor Fitzgerald 2018 Global Healthcare Conference
ChemoCentryx, Inc., (Nasdaq: CCXI), today announced that Thomas J. Schall, Ph.D., President and Chief Executive Officer, will present at the Cantor Fitzgerald 2018 Global Healthcare Conference on Tuesday October 2, 2018 at 1:40 p.m. ET. The...
Aug 28, 2018 08:30 am ET
ChemoCentryx to Present at Two Upcoming Investor Conferences
ChemoCentryx, Inc., (Nasdaq: CCXI), today announced that Thomas J. Schall, Ph.D., President and Chief Executive Officer, will present at two upcoming investor conferences in September: 20th Annual Rodman Renshaw Global Investment...
Aug 20, 2018 08:20 am ET
Recent Analysis Shows Ferroglobe, AXT, ChemoCentryx, RedHill Biopharma, GTx, and Achillion Pharmaceuticals Market Influences — Renewed Outlook, Key Drivers of Growth
In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of Ferroglobe PLC (NASDAQ:GSM), AXT Inc (NASDAQ:AXTI), ChemoCentryx, Inc....
Aug 09, 2018 04:05 pm ET
ChemoCentryx Reports Second Quarter 2018 Financial Results and Recent Highlights
ChemoCentryx, Inc., (Nasdaq:CCXI), today announced financial results for the second quarter ended June 30, 2018 and provided an overview of the Company's recent corporate highlights. "A most important milestone has recently been achieved at...
Aug 02, 2018 08:30 am ET
ChemoCentryx to Hold Second Quarter 2018 Financial Results Conference Call on Thursday, August 9, 2018
ChemoCentryx, Inc., (Nasdaq: CCXI), today announced that the Company's second quarter 2018 financial results will be released after market close on Thursday, August 9, 2018. ChemoCentryx executive management will host a conference call and webcast...
Jun 04, 2018 08:20 am ET
Report: Exploring Fundamental Drivers Behind Mitel Networks, Celestica, CoreCivic, Inc., Jazz Pharmaceuticals, Open Text, and ChemoCentryx — New Horizons, Emerging Trends, and Upcoming Developments
In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of Mitel Networks Corporation (NASDAQ:MITL), Celestica, Inc. (NYSE:CLS),...
May 30, 2018 08:30 am ET
ChemoCentryx to Present at Two Upcoming Investor Conferences
ChemoCentryx, Inc., (Nasdaq:CCXI), today announced that Thomas J. Schall, Ph.D., President and Chief Executive Officer, will present at two upcoming investor conferences in June: Jefferies 2018 Global Healthcare ConferenceCorporate Overview:...
May 23, 2018 08:30 am ET
ChemoCentryx Announces Two Upcoming Presentations at the 55th ERA-EDTA Congress
ChemoCentryx, Inc., (Nasdaq:CCXI), today announced two upcoming presentations during the 55th European Renal Association - European Dialysis and Transplant Association (ERA-EDTA) Congress, being held in collaboration with the Danish Society of...
May 09, 2018 04:05 pm ET
ChemoCentryx Reports First Quarter 2018 Financial Results and Recent Highlights
-- Ongoing clinical trials with avacopan in C3 Glomerulopathy (C3G) and CCX140 in Focal Segmental Glomerulosclerosis (FSGS), diseases with no approved therapies -- -- Expanding into orphan dermatological disease, with plan for clinical trials of...
May 02, 2018 08:30 am ET
ChemoCentryx to Hold First Quarter 2018 Financial Results Conference Call on Wednesday, May 9, 2018
MOUNTAIN VIEW, Calif., May 02, 2018 (GLOBE NEWSWIRE) -- ChemoCentryx, Inc., (Nasdaq:CCXI), today announced that the Company's first quarter 2018 financial results will be released after market close on Wednesday, May 9, 2018. ChemoCentryx executive management will host...
Apr 11, 2018 04:05 pm ET
ChemoCentryx Announces Presentation During National Kidney Foundation 2018 Spring Clinical Meeting
MOUNTAIN VIEW, Calif., April 11, 2018 (GLOBE NEWSWIRE) -- ChemoCentryx, Inc., (Nasdaq:CCXI), today announced the presentation of positive safety, efficacy and quality of life results from the Company’s successfully completed Phase II CLEAR and CLASSIC clinical trials of...
Apr 10, 2018 07:45 am ET
Recent Analysis Shows Ericsson, Toronto Dominion Bank, Odonate Therapeutics, Colliers International Group, ChemoCentryx, and CyberArk Software Market Influences — Renewed Outlook, Key Drivers of Growt
NEW YORK, April 10, 2018 (GLOBE NEWSWIRE) -- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of Ericsson (NASDAQ:ERIC), Toronto Dominion Bank (NYSE:TD),...
Apr 03, 2018 08:30 am ET
ChemoCentryx to Present at Two Upcoming Investor Conferences
MOUNTAIN VIEW, Calif., April 03, 2018 (GLOBE NEWSWIRE) -- ChemoCentryx, Inc., (Nasdaq:CCXI), today announced that Thomas J. Schall, Ph.D., President and Chief Executive Officer, will present at two upcoming investor conferences in April:
Mar 22, 2018 08:30 am ET
ChemoCentryx Publishes Novel Findings of Role of CCR2 in Kidney Glomerulus, Supporting Advancement of CCR2 Inhibitor CCX140 in the Treatment of Focal Segmental Glomerulosclerosis (FSGS)
-- Peer-reviewed findings show blocking CCR2 provides rapid and sustained renal benefit in well-established models of FSGS --
Mar 14, 2018 07:30 am ET
Research Report Identifies VimpelCom, NetEase, Altisource Portfolio Solutions S.A., CyrusOne, Global Indemnity, and ChemoCentryx with Renewed Outlook — Fundamental Analysis, Calculating Forward Moveme
NEW YORK, March 14, 2018 (GLOBE NEWSWIRE) -- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of VimpelCom Ltd. (NASDAQ:VEON), NetEase, Inc. (NASDAQ:NTES),...
Mar 09, 2018 07:00 am ET
ChemoCentryx Reports Fourth Quarter and Full Year 2017 Financial Results and Recent Highlights
-- Phase III ADVOCATE trial of avacopan in treatment of ANCA vasculitis nears 75% of patient enrollment target as European Medicine Agency continues review process of Conditional Marketing Authorization application --
Mar 06, 2018 08:30 am ET
ChemoCentryx to Present at the Cowen and Company 38th Annual Health Care Conference
MOUNTAIN VIEW, Calif., March 06, 2018 (GLOBE NEWSWIRE) -- ChemoCentryx, Inc., (Nasdaq:CCXI), today announced that Thomas J. Schall, Ph.D., President and Chief Executive Officer, will present at the Cowen and Company 38th Annual Health Care Conference on Tuesday...
Mar 01, 2018 08:30 am ET
ChemoCentryx to Hold Fourth Quarter 2017 Financial Results Conference Call on Friday, March 9, 2018
MOUNTAIN VIEW, Calif., March 01, 2018 (GLOBE NEWSWIRE) -- ChemoCentryx, Inc., (Nasdaq:CCXI), today announced that the Company's fourth quarter 2017 financial results will be released before market open on Friday, March 9, 2018. ChemoCentryx executive management will host...
Jan 22, 2018 05:00 pm ET
ChemoCentryx Announces Positive Overall Survival Results with CCR2 Inhibitor CCX872 for Locally Advanced/Metastatic Pancreatic Cancer
-- CCX872 plus FOLFIRINOX resulted in overall survival of 29 percent at 18 months in all patients --
Jan 08, 2018 08:30 am ET
ChemoCentryx Strengthens Senior Executive Team with the Appointment of William Fairey as Executive Vice President and Chief Operating Officer
MOUNTAIN VIEW, Calif., Jan. 08, 2018 (GLOBE NEWSWIRE) -- ChemoCentryx, Inc., (Nasdaq:CCXI), a biopharmaceutical company developing new medications targeted at inflammatory and autoimmune diseases and cancer, today announced the appointment of William (Bill) Fairey as Executive Vice President...
Jan 04, 2018 07:05 am ET
ChemoCentryx Secures up to $100 Million in New Capital Commitments
-- ChemoCentryx to Receive $50 Million Milestone from Vifor Pharma for Validation of Conditional Marketing Authorization Application for Avacopan for the Treatment of ANCA Vasculitis --
Jan 04, 2018 07:00 am ET
Avacopan Conditional Marketing Authorization Application Accepted for Regulatory Review by European Medicines Agency
VIFOR FRESENIUS MEDICAL CARE RENAL PHARMA AND CHEMOCENTRYX ANNOUNCE THAT THE EUROPEAN MEDICINES AGENCY HAS ACCEPTED FOR REVIEW THE REGISTRATION DOSSIER IN SUPPORT OF A CONDITIONAL MARKETING AUTHORIZATION FOR AVACOPAN IN THE TREATMENT OF PATIENTS WITH ANCA-ASSOCIATED VASCULITIS.
Jan 03, 2018 08:30 am ET
ChemoCentryx to Present at the 36th Annual J.P. Morgan Healthcare Conference
MOUNTAIN VIEW, Calif., Jan. 03, 2018 (GLOBE NEWSWIRE) -- ChemoCentryx, Inc., (Nasdaq:CCXI), a biopharmaceutical company developing new medications targeted at inflammatory and autoimmune diseases and cancer, today announced that Thomas J. Schall, Ph.D., President and Chief Executive Officer,...
Nov 17, 2017 08:30 am ET
ChemoCentryx to Participate at the Piper Jaffray 29th Annual Healthcare Conference
MOUNTAIN VIEW, Calif., Nov. 17, 2017 (GLOBE NEWSWIRE) -- ChemoCentryx, Inc., (Nasdaq:CCXI), a biopharmaceutical company developing new medications targeted at inflammatory and autoimmune diseases and cancer, today announced that Thomas J. Schall, Ph.D., President and Chief Executive Officer,...
Nov 07, 2017 04:40 pm ET
ChemoCentryx Reports Third Quarter 2017 Financial Results and Recent Highlights
-- Phase III ADVOCATE trial of avacopan remains on track to complete enrollment in mid-2018 --...
Nov 07, 2017 04:40 pm ET
ChemoCentryx Reports Third Quarter 2017 Financial Results and Recent Highlights
-- Phase III ADVOCATE trial of avacopan remains on track to complete enrollment in mid-2018 --
Nov 03, 2017 08:31 am ET
Presentations at ASN Kidney Week 2017 Highlight ChemoCentryx Platform in Treatment of Kidney Diseases ANCA-Associated Vasculitis and Focal Segmental Glomerulosclerosis (FSGS)
-- Rapid reduction in kidney inflammation following avacopan treatment in patients with ANCA-Associated Vasculitis revealed by analysis of markers of kidney damage --
Aug 08, 2017 04:05 pm ET
ChemoCentryx Reports Second Quarter 2017 Financial Results and Recent Highlights
-- Pivotal Phase III ADVOCATE trial of avacopan on track to complete enrollment in mid-2018 as projected --...
Jul 26, 2017 08:30 am ET
ChemoCentryx to Hold Second Quarter 2017 Financial Results Conference Call on Tuesday, August 8, 2017
MOUNTAIN VIEW, Calif., July 26, 2017 (GLOBE NEWSWIRE) -- ChemoCentryx, Inc., (Nasdaq:CCXI), a biopharmaceutical company developing new medications targeted at inflammatory and autoimmune diseases and cancer, today announced that the Company's second quarter 2017 financial results will be released after market close on Tuesday, August 8, 2017. ChemoCentryx executive management will host a conference call beginning at 5:00 p.m. Eastern Time on Tuesday, August 8, 2017, to discuss these results and to answer questions....
May 23, 2017 08:30 am ET
ChemoCentryx Granted EU Orphan Drug Designation for Avacopan in the Treatment of Debilitating Kidney Disease C3 Glomerulopathy (C3G)
MOUNTAIN VIEW, Calif., May 23, 2017 (GLOBE NEWSWIRE) -- ChemoCentryx, Inc., (Nasdaq:CCXI), a biopharmaceutical company developing new medications targeted at inflammatory and autoimmune diseases and cancer, announced today that the European Medicines Agency (EMA) has granted orphan medicinal product designation for avacopan (formerly CCX168) in the treatment of patients with C3 glomerulopathy (C3G)....
May 10, 2017 04:05 pm ET
ChemoCentryx Reports First Quarter 2017 Financial Results
-- Phase III clinical trial of avacopan for the treatment of ANCA Vasculitis underway as Journal of American Society of Nephrology (JASN) publishes results of successful Phase II CLEAR clinical trial --...
Apr 27, 2017 08:30 am ET
ChemoCentryx to Hold First Quarter 2017 Financial Results Conference Call on Wednesday, May 10, 2017
MOUNTAIN VIEW, Calif., April 27, 2017 (GLOBE NEWSWIRE) -- ChemoCentryx, Inc., (Nasdaq:CCXI), today announced that the Company's first quarter 2017 financial results will be released after market close on Wednesday, May 10, 2017. ChemoCentryx executive management will host a conference call beginning at 5:00 p.m. Eastern Time on Wednesday, May 10, 2017, to discuss these results and to answer questions....
Jan 20, 2017 03:30 pm ET
ChemoCentryx Announces Presentation of Data from Ongoing Phase Ib Clinical Trial of CCR2 Inhibitor CCX872 in Patients with Advanced Non-Resectable Pancreatic Cancer
MOUNTAIN VIEW, Calif., Jan. 20, 2017 (GLOBE NEWSWIRE) -- ChemoCentryx, Inc., (Nasdaq:CCXI) today announced the presentation of results from its immuno-oncology program at the American Society of Clinical Oncology (ASCO) 2017 Gastrointestinal Cancers Symposium being held January 19-21, 2017 in San Francisco, California....
Oct 28, 2016 08:30 am ET
ChemoCentryx to Hold Third Quarter 2016 Financial Results Conference Call on Monday, November 7, 2016
MOUNTAIN VIEW, Calif., Oct. 28, 2016 (GLOBE NEWSWIRE) -- ChemoCentryx, Inc., (Nasdaq:CCXI), today announced that the Company's third quarter 2016 financial results will be released after market close on Monday, November 7, 2016. ChemoCentryx executive management will host a conference call beginning at 5:00 p.m. Eastern Time on November 7, 2016, to discuss these results and to answer questions....
Oct 27, 2016 08:30 am ET
ChemoCentryx Reports Improvement in Renal Physiology and Stabilization of Kidney Function Following Treatment with Orally Administered Complement Inhibitor CCX168 (Avacopan) in Patient with Refractory
MOUNTAIN VIEW, Calif., Oct. 27, 2016 (GLOBE NEWSWIRE) -- ChemoCentryx, Inc., (Nasdaq:CCXI), today announced that its orally administered complement 5a receptor inhibitor CCX168 (newly designated “avacopan”) has shown a beneficial effect on disease in a patient with C3 glomerulopathy (C3G). C3G is a rare disease of the kidney characterized by deposition of the protein known as C3 (a component of the body’s complement system) in the filtration units (the glomeruli) of the kidney, leading to profound kidney damage and eventual renal failure. There is currently no approved effective standard t...
Oct 20, 2016 08:30 am ET
ChemoCentryx Appoints Henry A. McKinnell, Jr. to Board of Directors
MOUNTAIN VIEW, Calif., Oct. 20, 2016 (GLOBE NEWSWIRE) -- ChemoCentryx, Inc., (Nasdaq:CCXI), today announced that effective October 17, 2016, Henry A. McKinnell, Jr, Ph.D., retired chairman and chief executive officer of Pfizer Inc., has been appointed to the Company’s Board of Directors. Dr. McKinnell brings significant leadership in operations, international alliances, and commercial experience to ChemoCentryx....
Oct 18, 2016 08:30 am ET
ChemoCentryx’s CCR2 Inhibitor CCX872 Shown to Reduce Liver Fibrosis in NASH Models
-- CCX872 reduced hepatic inflammation, steatosis, and scarring in models of non-alcoholic steatohepatitis (NASH) --...
Oct 17, 2016 08:30 am ET
ChemoCentryx Announces Presentation of Positive Data from Ongoing Pilot Phase II Trial of CCX168 (Avacopan) in Atypical Hemolytic Uremic Syndrome (aHUS) at ASN Kidney Week 2016
MOUNTAIN VIEW, Calif., Oct. 17, 2016 (GLOBE NEWSWIRE) -- ChemoCentryx, Inc., (Nasdaq:CCXI), today announced that positive data from an ongoing Phase II proof-of-concept study of CCX168 for the treatment of Atypical Hemolytic Uremic Syndrome (aHUS) will be presented at the American Society of Nephrology (ASN) Kidney Week 2016 Annual Meeting. CCX168 (newly designated “avacopan”) is an orally-administered small molecule that is a selective inhibitor of the complement C5a receptor, or C5aR.  CCX168 (avacopan) is a lead drug candidate in the Company's orphan and rare disease program....
Sep 01, 2016 04:05 pm ET
ChemoCentryx Reports Initial Results from Ongoing Phase Ib Clinical Trial of CCX872 in Patients with Advanced Pancreatic Cancer
MOUNTAIN VIEW, Calif., Sept. 01, 2016 (GLOBE NEWSWIRE) -- ChemoCentryx, Inc., (Nasdaq:CCXI) today announced initial 12 week overall response rate (ORR) results from an ongoing open label, single arm Phase Ib clinical trial with CCX872 in patients with advanced pancreatic cancer. CCX872 is a selective inhibitor of the chemokine receptor known as CCR2....
Aug 25, 2016 08:30 am ET
ChemoCentryx to Present at the Baird 2016 Global Healthcare Conference
MOUNTAIN VIEW, Calif., Aug. 25, 2016 (GLOBE NEWSWIRE) -- ChemoCentryx, Inc., (Nasdaq:CCXI), a clinical-stage biopharmaceutical company developing orally-administered therapeutics to treat autoimmune diseases, inflammatory disorders, and cancer, today announced that Thomas J. Schall, Ph.D., President and Chief Executive Officer, will present at the Baird 2016 Global Healthcare Conference on Wednesday, September 7, 2016 at 3:45 p.m. ET. The conference will be held at the New York Palace Hotel in New York, NY....
Aug 08, 2016 04:05 pm ET
ChemoCentryx Reports Second Quarter 2016 Financial Results and Provides Corporate Update
-- Successfully Completed Phase II ANCA-Associated Vasculitis (AAV) Development Program of Complement 5a Receptor Inhibitor CCX168 --...
Aug 01, 2016 08:30 am ET
ChemoCentryx to Hold Second Quarter 2016 Financial Results Conference Call on Monday, August 8, 2016
MOUNTAIN VIEW, Calif., Aug. 01, 2016 (GLOBE NEWSWIRE) -- ChemoCentryx, Inc., (Nasdaq:CCXI), a clinical-stage biopharmaceutical company developing orally-administered therapeutics to treat autoimmune diseases, inflammatory disorders and cancer, today announced that the Company's second quarter 2016 financial results will be released after market close on Monday, August 8, 2016. ChemoCentryx executive management will host a conference call beginning at 5:00 p.m. Eastern Time on August 8, 2016, to discuss these results and to answer questions....
Jun 29, 2016 08:30 am ET
ChemoCentryx to Present at the Cantor Fitzgerald 2nd Annual Healthcare Conference
MOUNTAIN VIEW, Calif., June 29, 2016 (GLOBE NEWSWIRE) -- ChemoCentryx, Inc., (Nasdaq:CCXI), a clinical-stage biopharmaceutical company developing orally-administered therapeutics to treat autoimmune diseases, inflammatory disorders, and cancer, today announced that Thomas J. Schall, Ph.D., President and Chief Executive Officer, will present at the Cantor Fitzgerald 2nd Annual Healthcare Conference on Wednesday, July 13, 2016 at 9:30 a.m. ET. The conference will be held at the Le Parker Meridien Hotel in New York, NY.   ...
Jun 16, 2016 08:30 am ET
ChemoCentryx Announces Positive Top-Line Results for CCX168 from the Phase II ANCA-Associated Vasculitis CLASSIC Study and Advances Plans to Initiate Phase III Development
-- Safety study objective achieved: CCX168 shown to be well tolerated in patients with ANCA-associated vasculitis when added to current standard of care regimen --...
Jun 01, 2016 08:30 am ET
ChemoCentryx Receives European Medicines Agency PRIority MEdicines (PRIME) Designation for Accelerated Assessment of Complement 5a Receptor Inhibitor CCX168 for Treatment of Patients with ANCA-Associa
MOUNTAIN VIEW, Calif., June 01, 2016 (GLOBE NEWSWIRE) -- ChemoCentryx, Inc., (Nasdaq:CCXI), a clinical-stage biopharmaceutical company developing orally-administered therapeutics to treat autoimmune diseases, inflammatory disorders, and cancer, today announced it received PRIority MEdicines (PRIME) designation from the European Medicines Agency (EMA) for CCX168 for the treatment of ANCA-Associated Vasculitis, or AAV. As described by the EMA, PRIME aims to bring promising innovative medicines to patients faster by optimizing and supporting medicine development. To be accepted for PRIME, a m...
May 25, 2016 08:30 am ET
ChemoCentryx to Present at the Jefferies 2016 Healthcare Conference
MOUNTAIN VIEW, Calif., May 25, 2016 (GLOBE NEWSWIRE) -- ChemoCentryx, Inc., (Nasdaq:CCXI), a clinical-stage biopharmaceutical company developing orally-administered therapeutics to treat autoimmune diseases, inflammatory disorders, and cancer, today announced that Thomas J. Schall, Ph.D., President and Chief Executive Officer, will present at the Jefferies 2016 Healthcare Conference on Wednesday, June 8, 2016 at 3:30 p.m. ET. The conference will be held at the Grand Hyatt Hotel in New York, NY...
May 23, 2016 09:15 am ET
ChemoCentryx Announces Presentation of Positive Results from Phase II ANCA-Associated Vasculitis CLEAR Trial of Orally Administered Complement 5a Receptor Inhibitor CCX168 at the 53rd ERA-EDTA Congres
-- Treatment with CCX168 successful in achieving clinical efficacy endpoints while eliminating high-dose oral corticosteroids from current standard-of-care regimen, suggesting a new treatment paradigm for ANCA-Associated Vasculitis --...
May 12, 2016 08:30 am ET
ChemoCentryx Announces Data Presentation of Novel CCR6 Inhibitors at the 2016 Society for Investigative Dermatology (SID) Annual Meeting
MOUNTAIN VIEW, Calif., May 12, 2016 (GLOBE NEWSWIRE) -- ChemoCentryx, Inc., (Nasdaq:CCXI), a clinical-stage biopharmaceutical company developing orally-administered therapeutics to treat autoimmune diseases, inflammatory disorders, and cancer, today announced that preclinical data using a series of orally-available inhibitors of the chemokine receptor known as CCR6, have been selected for a poster presentation at the 2016 Society for Investigational Dermatology Annual Meeting, being held May 11-14, 2016 in Scottsdale, Arizona....
May 11, 2016 08:30 am ET
ChemoCentryx to Host R&D Day on May 18, 2016
MOUNTAIN VIEW, Calif., May 11, 2016 (GLOBE NEWSWIRE) -- ChemoCentryx, Inc., (Nasdaq:CCXI), a clinical-stage biopharmaceutical company developing orally-administered therapeutics to treat autoimmune diseases, inflammatory disorders and cancer, today announced that the Company will host an R&D Day on Wednesday, May 18, 2016 at 12:00 p.m. Eastern Time in New York, NY. The Company will be joined by several leading physicians....
May 10, 2016 07:05 am ET
ChemoCentryx Reports First Quarter 2016 Financial Results and Provides Corporate Update
- Company Announces Exclusive License Agreement with Vifor Pharma to Commercialize Orally Administered Complement 5a Receptor Inhibitor CCX168 in Europe and Certain Other Markets; Agreement Includes $85 Million Upfront, Comprising $60 Million in Cash in Addition to $25 Million Equity Investment -...
May 10, 2016 07:00 am ET
Vifor Pharma Licenses Rights to Commercialize ChemoCentryx’s Orally-Administered Complement 5aR Inhibitor CCX168 for Orphan and Rare Renal Diseases in Europe and Certain Other Major Markets
- Vifor Pharma to market drug in selected territories outside the US, ChemoCentryx responsible for worldwide development of CCX168 -...
May 05, 2016 08:30 am ET
ChemoCentryx to Hold First Quarter 2016 Financial Results Conference Call on Tuesday, May 10, 2016
MOUNTAIN VIEW, Calif., May 05, 2016 (GLOBE NEWSWIRE) -- ChemoCentryx, Inc., (Nasdaq:CCXI), a clinical-stage biopharmaceutical company developing orally-administered therapeutics to treat autoimmune diseases, inflammatory disorders and cancer, today announced that the Company's first quarter 2016 financial results will be released before market open on Tuesday, May 10, 2016. ChemoCentryx executive management will host a conference call beginning at 8:30 a.m. Eastern Time on May 10, 2016, to discuss these results and to answer questions....
Apr 28, 2016 08:30 am ET
ChemoCentryx Receives FDA Orphan Products Development Grant for Orally Administered Complement 5a Receptor Inhibitor CCX168 for Treatment of ANCA-Associated Vasculitis
MOUNTAIN VIEW, Calif., April 28, 2016 (GLOBE NEWSWIRE) -- ChemoCentryx, Inc., (Nasdaq:CCXI), a clinical-stage biopharmaceutical company developing orally-administered therapeutics to treat autoimmune diseases, inflammatory disorders and cancer, today announced that the U.S. Food and Drug Administration (FDA) has awarded the Company a one-year grant of $500,000 to assist in the clinical development of CCX168, the Company’s lead drug candidate for the treatment of patients with anti-neutrophil cytoplasmic antibody (ANCA) -associated vasculitis, or AAV. CCX168 is an orally-administered small ...